Precision Therapeutics has booked up $43 million in a sixth round of funding. The money will be used to expand the development and commercialization of ChemoFx, a lab test that predicts how patient's cancer cells will respond to different chemotherapy agents prior to initiating the treatment. Longitude Venture Partners led the round, which also included Adams Capital Management, Quaker BioVentures, Birchmere Ventures, Techno Venture Management and Draper Triangle Ventures.
"This funding will allow us to expand our penetration of the market and aggressively pursue new programs that will further enhance a physician's ability to determine individualized therapy regimens for patients in need," said Precision CEO Sean McDonald. The company has raised a total of $125 million since it was created in 1995.
- check out Precision's release
PLUS Safeguard Scientifics and Oxford Bioscience Partners co-led a $12 million Series A financing round with Oxford Bioscience Partners for Molecular Biometrics. The metabolomics company's lead product, ViaMetrics-ETM, is a diagnostic procedure designed to help identify the most viable embryos with the greatest reproductive potential for in vitro fertilization. Molecular Biometrics' release
ALSO: Psyadon Pharmaceuticals has raised $8 million in Series A-1 funding from return backer New Enterprise Associates. The Maryland-based drug developer will use the funds to advance clinical development of ecopipam for the treatment of serious central nervous system disorders. Report
AND: Germany's JADO Technologies has raised €3.9 million in a Series B financing led by Peppermint Financial Partners. The proceeds will be used to advance two formulations of JADO's lead clinical-stage compound, TF002, through the rest of Phase II trials in both atopic dermatitis and urticaria. JADO will also advance second generation allergy compounds to proof of principle in animal in asthma. JADO release